Infinium Pharmachem Limited

NSEI:INFINIUM Stock Report

Market Cap: ₹4.4b

Infinium Pharmachem Valuation

Is INFINIUM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of INFINIUM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: INFINIUM (₹317.25) is trading above our estimate of fair value (₹198.64)

Significantly Below Fair Value: INFINIUM is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for INFINIUM?

Key metric: As INFINIUM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for INFINIUM. This is calculated by dividing INFINIUM's market cap by their current earnings.
What is INFINIUM's PE Ratio?
PE Ratio46.5x
Earnings₹94.99m
Market Cap₹4.41b

Price to Earnings Ratio vs Peers

How does INFINIUM's PE Ratio compare to its peers?

The above table shows the PE ratio for INFINIUM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average64.8x
530163 Kerala Ayurveda
161.5xn/a₹4.7b
531739 Gennex Laboratories
23.2xn/a₹4.0b
526953 Venus Remedies
20.1xn/a₹4.5b
540937 Medico Remedies
54.2xn/a₹4.2b
INFINIUM Infinium Pharmachem
46.5xn/a₹4.4b

Price-To-Earnings vs Peers: INFINIUM is good value based on its Price-To-Earnings Ratio (46.5x) compared to the peer average (64.8x).


Price to Earnings Ratio vs Industry

How does INFINIUM's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.8xn/aUS$79.01m
524652 Ind-Swift
2.7xn/aUS$17.70m
No more companies available in this PE range
INFINIUM 46.5xIndustry Avg. 35.2xNo. of Companies20PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: INFINIUM is expensive based on its Price-To-Earnings Ratio (46.5x) compared to the Indian Pharmaceuticals industry average (35.8x).


Price to Earnings Ratio vs Fair Ratio

What is INFINIUM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

INFINIUM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio46.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate INFINIUM's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies